AES INC. EXPANDS INTO BIOLOGIC
MANUFACTURING WITH LAUNCH OF AES BIOLOGICS CDMO

The newdivision expands AES’s integrated biotech model into GMP manufacturing, accelerating First-in-Human (FIH) development for emerging innovators.

Automated Engineering Services, Inc (AES), a leader in process engineering, automation, and integrated biotech solutions, today announced the launch of AES Biologics, a dedicated contract development and manufacturing organization (CDMO) focused on boutique microbial fermentation and early-stage clinical programs. 

AES Biologics will operate as an independently positioned biologics manufacturing division with the AES family of companies, extending AES’s engineering-first approach into GMP clinical production.

Addressing the Gap in Microbial CDMO Services

Emerging biopharma companies developing recombinant proteins and therapeutic enzymes frequently face prolonged timelines, rigid CDMO processes, and high costs that delay proof-of-concept and investor milestones. AES Biologics was created to address these challenges by combining:

• Rapid Tech Transfer
• FIH-ready Pilot GMP Suites
• Advanced microbial process development
• Integrated automation and data systems

 

This model enables startups to move from strain development to clinical materials faster, with greater flexibility and regulatory control. 

By embedding Engineering and digital process control early in development, AES Biologics aims to reduce industry-standard development timelines while de-risking programs for biotech innovators seeking domestic U.S.-based manufacturing partners.

Phase I Capabilities

AES Biologics launches with capabilities designed to support pre-clinical and First-in-Human (FIH) programs:

Core Analytical Lab (FIH-Ready)

GMP assays for identity, purity, potency, and safety.

Process Development Lab

Strain engineering, microbial fermentation, and three-column downstream purification.

Pilot Manufacturing

GMP production at 10–500L scale.

Semi-Automated Vial Filling

Early-stage fill for reference standards, toxicology studies, and preclinical material.

Pairing automation with standardized buffers and reagents enhances reproducibility, reduces human error, and establishes scalable GMP-ready workflows from the outset. This foundation supports difficult-to-express proteins and therapeutic enzymes, and supports future expansion into high-demand modalities such as live biotherapeutics (LBPs) and plasmid DNA (pDNA) supply.

Built on AES Engineering & Regulatory Expertise

Built on a foundation of more than 100 combined years of scientific, GMP, regulatory, and operational experience—including support for over 100 FDA inspections—AES Biologics enters the CDMO space with proven global credibility.

As part of the AES ecosystem, clients benefit from seamless integration across:

• Process Engineering
• Automation & Systems Integration
• Data Management & Digital Infrastructure
• OEM Equipment Manufacturing
• Biotech Staffing & GMP Workforce Scaling

 

This unified platform enables clients to move beyond one-off projects toward long-term, multi-year biotech partnerships with scalable, automation-ready infrastructure.

Leadership Perspective

“AES Biologics represents the natural evolution of our integrated biotech model,” said Leo Castaneda, CEO of Automated Engineering Services, Inc. “For years, we’ve supported innovators with engineering, automation, and GMP readiness. Now, we’re bringing that expertise directly into early-stage biologic manufacturing—giving startups a partner who understands both the science and the systems required to scale.”

He added, “Startups don’t just need manufacturing capacity—they need speed, flexibility, and regulatory confidence. AES Biologics is built to deliver all three.”

Partner with AES

AES Biologics is now accepting partnerships with biotechnology companies advancing microbial-based programs toward clinical readiness.

For partnership inquiries, visit www.aesbiologics.com or contact Mike Taylor, Sr. Director of Business Development of CDMO

 

About AES Biologics

AES Biologics is an independently operating contract development and manufacturing organization (CDMO) powered by the engineering, automation, scientific, and regulatory expertise of Automated Engineering Services (AES). Focused on early-stage biologic programs, AES Biologics provides U.S.-based, GMP-compliant microbial fermentation, analytical, and pilot manufacturing solutions designed for speed, flexibility, and process control. The company’s roadmap includes expansion into live biotherapeutics (LBPs) and plasmid DNA (pDNA) manufacturing.

About Automated Engineering Services, Inc. (AES)

Automated Engineering Services, Inc. (AES) delivers integrated biotech solutions spanning process engineering, automation & integration, data management, OEM equipment manufacturing, staffing, facility qualification, and GMP readiness. With decades of global regulatory experience and a reputation for engineering excellence, AES partners with biotechnology innovators to design, scale, and operationalize compliant manufacturing environments worldwide.

Media Contact

Amelia Barth

Senior Marketing Manager

amelia.barth@thinkaes.com